Clinical studies of two forms of a vaccine against the virus SARS-CoV-2 (of the pathogen coronavirus infection COVID-19) started in Russia today, June 17, according to the Ministry of health. The tests will be carried out on two groups of volunteers for 38 people each. The first of them will be vaccinated in the next two days.
“the studies of the two forms of the vaccine: liquid and lyophilized — will be carried out in two medical institutions in Moscow. The vaccine in the form of a solution for intramuscular injection will be conducted in a military hospital named after Burdenko. Another, in the form of powder for preparation of solution for intramuscular injection is in Sechenovskiy University,” — said the Ministry of health of the Russian Federation. Both forms of the vaccine was developed by the National research centre of epidemiology and Microbiology. N. F. Gamalei. Permission to test was issued on June 16.
“conduct a clinical trial directly during a pandemic is a unique case. Were therefore taken unprecedented measures to potential study participants who will only be screened, two weeks were in a sanatorium for observation”, — stated in the message.
After vaccination of volunteers awaits isolation in hospital for 28 days. The doctors will monitor their health and the formation of immune response by blood tests. After discharge to monitor the health of the volunteers will continue for six months.
Recall that the world health organization (who) believes that without effective vaccine to cope with the pandemic coronavirus impossible. Studies are being conducted simultaneously in different countries. The first vaccine may not appear until 2021, said earlier the representative of who in Russia, Melita Vujnović. The Russian authorities were more optimistic: according to Deputy Prime Minister Dmitry Chernyshenko, mass vaccination of Russians from the coronavirus could begin in the fall of 2020. The first vaccine, which will appear on the market, will not help to stop the spread of COVID-19, say scientists polled by Bloomberg.
